Camlin Fine Sciences Limited
NSE: CAMLINFINEMarket Closed • NSE
Day range
52 week range
Camlin Fine Sciences Limited closed at INR95.09 (+6.26%) on volume 3.42x its 20-day average, trading 53.52% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -135.9% QoQ
2025-01-08
RIGHTS Announced
Rights 5:41 @ Premium Rs 109/-
2024-07-24
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
High Cash Flow Conversion: CFO/PAT averaged 3.18x over last 3 years
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Specialty Chemicals.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 08 Jan 2025 | Rights issue | Rights 5:41 @ Premium Rs 109/- | — | 08 Jan 2025 |
| — | Annual General Meeting | Annual General Meeting | — | 24 Jul 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 24 Jul 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Jul 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 12 Jul 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 31 Jul 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 25 Jul 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 03 Aug 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 13 Jul 2017 |
| — | Dividend | ₹0.45 / share | — | 28 Jul 2016 |
| — | Dividend | ₹0.45 / share | — | 27 Jul 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 UltraTech Cement LimitedULTRACEMCO Open analysis | ₹3.21L | 37.59 | 2.21% | ₹25,799.47 | ₹2,982.76 | +11.86% | +20.17% |
 JSW Steel LimitedJSWSTEEL Open analysis | ₹2.97L | 12.05 | 0.59% | ₹47,364.00 | ₹4,651.00 | +11.55% | +112.96% |
 Hindustan Zinc LimitedHINDZINC Open analysis | ₹2.28L | 13.37 | 2.07% | ₹13,687.00 | ₹5,425.00 | +77.22% | +146.14% |
 Asian Paints LimitedASIANPAINT Open analysis | ₹2.24L | 46.94 | 1.17% | ₹10,541.94 | ₹1,539.25 | +17.94% | +39.96% |
 Tata Steel LimitedTATASTEEL Open analysis | ₹2.19L | 19.83 | 2.27% | ₹60,794.00 | ₹2,385.00 | +14.32% | +18.83% |
 Hindalco Industries LimitedHINDALCO Open analysis | ₹2.02L | 12.32 | 0.56% | ₹84,825.00 | ₹7,013.00 | +32.06% | +75.15% |
 Grasim Industries LimitedGRASIM Open analysis | ₹1.98L | 34.82 | 0.35% | ₹11,794.71 | ₹246.65 | -70.60% | -82.61% |
 Solar Industries India LimitedSOLARINDS Open analysis | ₹1.81L | 90.93 | 0.06% | ₹3,668.00 | ₹666.00 | +70.29% | +88.67% |
Camlin Fine Sciences is engaged in the Business of Speciality Chemicals.
IndiaBasic Materials
Is Camlin Fine Sciences Limited Shariah compliant?
Camlin Fine Sciences Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (71.95%) exceeds AAOIFI threshold (≤ 33%).
What is Camlin Fine Sciences Limited's current valuation relative to peers?
Camlin Fine Sciences Limited trades at a P/E of N/A compared to the sector median of 21.9x, and a Price-to-Book of 1.8x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.72x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 1.1% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.